CSPC Pharmaceutical Group Limited (HKEX:1093) Annual Report 2021



The latest annual report of CSPC Pharmaceutical Group Limited (1093) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - 1093 Annual Results

Amounts in CNY

Total Revenue
27.87B
Gross Profit
21.14B
EBIT
6.25B
Net Tangible Assets
25.41B
Net Income
5.61B
Capital Expenditures
-1.41B

1093 Income Statement 2021 Annual Report

As per the latest Income Statement of 1093, the Net revenue increased by ¥2.924666B (12%) compared to the previous period. The operating income in 2021 increased by ¥777.11M (14%). The net income as per the annual report was 5.61B which increased by ¥445.53M (9%) compared to previous year.

Income Statement Report (2021/2020)

2021 2020
Total Revenue 27.87B 24.94B
Gross Profit 21.14B 18.69B
Operating Income 6.25B 5.47B
Income Before Tax 6.85B 6.39B
Net Income 5.61B 5.16B

Balance Sheet - 1093 2021 Annual Report

Read further: 1093 Balance Sheet Detailed Analysis

The latest balance sheet from annual result of CSPC Pharmaceutical Group Limited showed the company increased the cash on balance sheet by ¥1.987613B (27%). The Net tangible assets of 1093 on the balance sheet were at 25.41B which is ¥3.723109B (17%) more than previous annual report. The total stockholder equity also increased by ¥3.654384B (16%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

2021 2020
Cash 9.28B 7.3B
Total Assets 34.74B 30.07B
Long Term Debt - -
Total Liabilities 7.91B 6.97B
Total Shareholder Equity 25.99B 22.33B
Net Tangible Assets 25.41B 21.69B

Cash Flow Statement - 1093 2021 Annual Report

The 2021 annual cash flow statement of CSPC Pharmaceutical Group Limited showed that the net income increased by ¥445.53M (9%) compared to previous reporting period. Also the capital expenditure of 1093 decreased by ¥-53.91M (-4%).

As of 2021, the total cash from investing activities was -637.33M and total cash from financing activities was -2.2B.

Cash Flow Statement Report (2021/2020)

2021 2020
Net Income 5.61B 5.16B
Capital Expenditures -1.41B -1.36B
Dividends Paid -1.69B -1.53B
Total Cash From From Investing Activities -637.33M -2.13B
Total Cash From From Financing Activities -2.2B -1.47B

CSPC Pharmaceutical Group Limited Annual Report History

Income Statement

Income Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Total Revenue 27.87B 24.94B 22.1B 17.72B
Cost Of Revenue 6.73B 6.26B 6.19B 5.98B
Gross Profit 21.14B 18.69B 15.91B 11.74B
Research Development 3.43B 2.89B 2B 1.34B
Selling General Administrative 11.45B 10.32B 9.46B 6.84B
Non Recurring - - - -
Other Operating Expenses - - - -59.57M
Total Operating Expenses 21.62B 19.47B 17.65B 14.1B
Operating Income 6.25B 5.47B 4.45B 3.61B
Total Other Income Expense Net 597.84M 918.87M 176.2M 178.46M
Ebit 6.25B 5.47B 4.45B 3.61B
Interest Expense -7.66M -12.23M -32.43M -74.34M
Income Before Tax 6.85B 6.39B 4.63B 3.79B
Income Tax Expense 1.16B 1.16B 892.81M 733.76M
Minority Interest 841.56M 768.78M 1.06B 477.34M
Net Income From Continuing Ops 5.69B 5.23B 3.73B 3.06B
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income 5.61B 5.16B 3.71B 3.08B
Net Income Applicable To Common Shares 5.61B 5.16B 3.71B 3.08B

Balance Sheet Statement

Balance Sheet Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Cash 9.28B 7.3B 4.12B 4.34B
Short Term Investments 580.42M 484.29M 536k 443k
Net Receivables 6.55B 4.74B 4.84B 3.89B
Inventory 2.48B 1.86B 2.54B 3.19B
Total Current Assets 20.34B 15.92B 13.7B 13.8B
Long Term Investments 2.92B 2.71B 1.49B 798.54M
Property Plant Equipment 9.56B 8.93B 9.28B 6.69B
Good Will 149.98M 149.98M 188.96M 140.75M
Intangible Assets 425.87M 494.6M 1.13B 799.96M
Other Assets 1.34B 1.86B 536.74M 981.87M
Deferred Long Term Asset Charges 43M 117.47M 34.84M 18.95M
Total Assets 34.74B 30.07B 26.32B 23.22B
Accounts Payable 1.77B 1.36B 1.53B 3.27B
Other Current Liab 2.25B 2.38B 2.7B 2.48B
Other Liab 631.68M 574.41M 473.08M 440.22M
Deferred Long Term Liab 41.98M 14.15M 8.08M 7.02M
Minority Interest 841.56M 768.78M 1.06B 477.34M
Total Current Liabilities 7.23B 6.3B 6.24B 7.25B
Total Liab 7.91B 6.97B 6.8B 7.69B
Common Stock 10.9B 10.9B 10.9B 10.9B
Retained Earnings 19.19B 15.2B 11.49B 8.74B
Treasury Stock -4.15B -3.81B -3.98B -4.64B
Capital Surplus 46.79M 46.79M 46.79M 46.79M
Other Stockholder Equity -4.06B -3.71B -3.88B -4.64B
Total Stockholder Equity 25.99B 22.33B 18.46B 15.05B
Net Tangible Assets 25.41B 21.69B 17.15B 14.11B
Long Term Debt - - - -

Cash Flow Statement

Cash Flow Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net Income 5.61B 5.16B 3.71B 3.08B
Depreciation 862.38M 804.45M 686.67M 607.41M
Change To Netincome -446.11M -909.03M -136.99M -145.9M
Change To Account Receivables -943.55M -445.45M -196.74M -519.66M
Change To Liabilities 232.57M 629.28M -572.97M 593.83M
Change To Inventory -617.07M 601.44M 509.31M -614.03M
Change To Operating Activities -59.87M 894.92M -224.41M 770.4M
Total Cash From Operating Activities 4.64B 6.74B 3.78B 3.8B
Capital Expenditures -1.41B -1.36B -1.88B -1.67B
Investments 630.71M -450.06M 261.06M -1.44B
Other Cashflows From Investing Activities 269M -10.01M -267.2M -190.05M
Total Cashflows From Investing Activities -637.33M -2.13B -2.46B -3.63B
Dividends Paid -1.69B -1.53B -965.38M -782.88M
Net Borrowings -222.17M 76.68M -1.63B 714.11M
Other Cashflows From Financing Activities -20.16M -19.96M 1.15B 809k
Total Cash From Financing Activities -2.2B -1.47B -1.55B -151.39M
Effect Of Exchange Rate -2.44M 2.1M 1.46M 3.01M
Change In Cash 1.8B 3.14B -217.38M 19.05M
Repurchase Of Stock -263.51M -263.51M -100.71M -83.43M